Integrated multimodal cell atlas of Alzheimer’s disease

Mariano I. Gabitto,Kyle J. Travaglini,Victoria M. Rachleff,Eitan S. Kaplan,Brian Long,Jeanelle Ariza,Yi Ding,Joseph T. Mahoney,Nick Dee,Jeff Goldy,Erica J. Melief,Anamika Agrawal,Omar Kana,Xingjian Zhen,Samuel T. Barlow,Krissy Brouner,Jazmin Campos,John Campos,Ambrose J. Carr,Tamara Casper,Rushil Chakrabarty,Michael Clark,Jonah Cool,Rachel Dalley,Martin Darvas,Song-Lin Ding,Tim Dolbeare,Tom Egdorf,Luke Esposito,Rebecca Ferrer,Lynn E. Fleckenstein,Rohan Gala,Amanda Gary,Emily Gelfand,Jessica Gloe,Nathan Guilford,Junitta Guzman,Daniel Hirschstein,Windy Ho,Madison Hupp,Tim Jarksy,Nelson Johansen,Brian E. Kalmbach,Lisa M. Keene,Sarah Khawand,Mitch Kilgore,Amanda Kirkland,Michael Kunst,Brian R. Lee,Mckaila Leytze,Christine L. Mac Donald,Jocelin Malone,Zoe Maltzer,Naomi Martin,Rachel McCue,Delissa McMillen,Gonzalo Mena,Emma Meyerdierks,Kelly P. Meyers,Tyler Mollenkopf,Mark Montine,Amber L. Nolan,Julie Nyhus,Paul A. Olsen,Maiya Pacleb,Chelsea M. Pagan,Nicholas Peña,Trangthanh Pham,Christina Alice Pom,Nadia Postupna,Christine Rimorin,Augustin Ruiz,Giuseppe A. Saldi,Aimee M. Schantz,Nadiya V. Shapovalova,Staci A. Sorensen,Brian Staats,Matt Sullivan,Susan M. Sunkin,Carol Thompson,Michael Tieu,Jonathan Ting,Amy Torkelson,Tracy Tran,Nasmil J. Valera Cuevas,Sarah Walling-Bell,Ming-Qiang Wang,Jack Waters,Angela M. Wilson,David Haynor,Nicole M. Gatto,Suman Jayadev,Shoaib Mufti,Lydia Ng,Shubhabrata Mukherjee,Paul K. Crane,Caitlin S. Latimer,Boaz P. Levi,Kimberly Smith,Jennie L. Close,Jeremy A. Miller,Rebecca D. Hodge,Eric B. Larson,Thomas J. Grabowski,Michael Hawrylycz,C. Dirk Keene,Ed S. Lein

DOI: https://doi.org/10.1101/2023.05.08.539485

2024-02-15

Abstract:Alzheimer’s disease (AD) is the most common cause of dementia in older adults. Neuropathological and imaging studies have demonstrated a progressive and stereotyped accumulation of protein aggregates, but the underlying molecular and cellular mechanisms driving AD progression and vulnerable cell populations affected by disease remain coarsely understood. The current study harnesses single cell and spatial genomics tools and knowledge from the BRAIN Initiative Cell Census Network to understand the impact of disease progression on middle temporal gyrus cell types. We used image-based quantitative neuropathology to place 84 donors spanning the spectrum of AD pathology along a continuous disease pseudoprogression score and multiomic technologies to profile single nuclei from each donor, mapping their transcriptomes, epigenomes, and spatial coordinates to a common cell type reference with unprecedented resolution. Pseudo-progression analysis showed two major epochs corresponding with a slow early increase in pathology and a later exponential increase that correlated with cognitive decline. The early phase included inflammatory microglial and reactive astrocyte component, as well as a selective loss of Sst+ inhibitory neuron types in superficial cortical layers, loss of myelinating oligodendrocytes, and up-regulation of a re-myelination program by OPCs. The later phase involved loss of excitatory neurons and Pvalb and Vip neuron subtypes also predominantly in superficial layers. These cell vulnerabilities were also seen in prefrontal cortex and replicated by other independent studies when integrated with the BRAIN Initiative reference. Study data and exploratory tools are freely available to accelerate progress in AD research at .

Genomics

What problem does this paper attempt to address?

The paper attempts to address the specific mechanisms by which Alzheimer's disease (AD) affects brain cell types at different pathological stages. Specifically, the study aims to:

1. **Understand the dynamic changes in cell types during AD progression**: By using single-cell and spatial genomics technologies, researchers hope to detail the changes in different cell types during AD progression, including molecular, transcriptomic, epigenomic, and spatial distribution changes.

2. **Identify key cellular events in early and late AD**: Researchers aim to identify the main cellular and molecular events in early and late AD by constructing a Continuous Pseudoprogression Score (CPS), thereby better understanding the pathogenesis of AD.

3. **Validate and integrate data from different studies**: By mapping data to the reference classification of the BRAIN Initiative Cell Census Network (BICCN), researchers hope to validate and integrate data from different studies to establish a comprehensive and consistent AD cell atlas.

4. **Explore cell changes in specific brain regions**: The research focuses on the Middle Temporal Gyrus (MTG), a brain region associated with language and semantic memory processing and a key area in AD progression. Researchers hope to reveal the cellular and molecular basis of AD progression by analyzing cell changes in this region.

5. **Provide high-quality data resources**: Researchers will publicly release the generated multimodal datasets, analysis tools, and exploration tools on the SEA-AD.org website, allowing other researchers to utilize these resources to accelerate AD research progress.

Through these objectives, researchers hope to provide important scientific evidence for the early diagnosis of AD, monitoring disease progression, and developing therapeutic strategies.